| Name | Title | Contact Details |
|---|
Havas Health & You is a unique health and wellness network focused on promoting healthy living decisions across the entire health ecosystem. We believe in putting YOU – our employees, business partners, and our customers – at the center of everything we do. By understanding what you need and crafting unique solutions, we can help you stay and live well.
McKesson Corporation, currently ranked 7th on the FORTUNE 500, we are a global healthcare services and medical supply company dedicated to delivering better care. We support the entire healthcare system, including pharmacies, hospitals, health systems, biotech and life sciences companies, specialty care and oncology practices, physician offices, surgery centers, and long-term care and home health facilities. We deliver pharmaceutical products, medical supplies and business services to each of these groups to create a world of better health.
OrphoMed is a San Francisco based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. OrphoMed dimers are protected by composition of matter and method of use patents.
Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Our products are designed with a thorough understanding of not only species-specific health issues, but also market practices, the economics of current treatment strategies, competitive dynamics, government initiatives, such as concern for extensive antibiotic usage, and effective channels for new product introductions. In addition to Canalevia™ for dogs and Neonorm™ for preweaned dairy calves, we are developing formulations of these products across multiple animal species and market channels. Our management team has significant experience in gastrointestinal and animal health product development. This experience includes the development of crofelemer for human use, from discovery and preclinical and clinical toxicity studies, including the existing animal studies to be used for Canalevia™ regulatory approvals, through human clinical development. Our team also includes individuals who have prior animal health experience at major pharmaceutical companies, including Ciba-Geigy Corp., now Novartis International AG, SmithKline Beecham Corporation, now GlaxoSmithKline LLC, and the animal health group of Pfizer Inc., now Zoetis Inc.
The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.